| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
SAN DIEGO—OptimerPharmaceuticals Inc. announced Oct. 8 the sale of the last of its stake inOptimer Biotechnology Inc. (OBI) to current OBI shareholders, with the sale expectedto result in gross proceeds to Optimer of $60 million that will be used tosupport the commercialization of Dificid (fidaxomicin) tablets and for othercorporate purposes.
 
The transaction is expected to close in two phases, subjectto customary closing conditions and the completion of administrative matters.The first closing is expected to take place in the fourth quarter of 2012 andthe second closing is expected to take place in the first quarter of 2013.
 
"The sale of our stake in OBI completes thetransition of OBI from a wholly-owned subsidiary of Optimer to an independentorganization. We intend to utilize the capital realized from this investment toadvance the commercial efforts in support of our core business, including ournew initiatives designed to increase patient access to Dificid," notedPedro Lichtinger, president and CEO of Optimer.
 
 
For the third quarter of 2012, Optimer's top-lineU.S. gross Dificid sales to wholesalers were $18.4 million, up from $18million in the second quarter. Further, 6,436 Dificid treatments were shippedfrom Optimer's wholesalers to hospitals, retail pharmacies and long-term carefacilities in the third quarter, up from 6,131 in the second quarter,reflecting a 5-percent increase, Optimer notes.
 
 
Optimer Pharmaceuticals is a globalbiopharmaceutical company focused on developing and commercializing innovativehospital specialty products that "have a positive impact on society." The company developed Dificid tablets and is commercializing the drug in theUnited States and Canada. Optimer also received marketing authorization for fidaxomicintablets in the European Union where its partner, Astellas Pharma Europe, iscommercializing fidaxomicin under the trade name DIFICLIR. The company isexploring marketing authorization in other parts of the world, including Asia.
 
OBI is a biotechcompany formed in Taiwan in 2002, structured at first as awholly owned subsidiary of Optimer Pharmaceuticals. In November 2009, it began to spin off from its parent company,forming a new management team with a mission to "develop noveltherapeutic agents for diseases that are currently lacking treatmentoptions," according to the company's website. The initial therapeutic focus of OPI right now is on cancer andosteoarthritis, but OBI says it "is positioned as a new product development companystriving to improve health and quality of life through innovative andcost effective medicine."
 
The most recent news coming out of OBI is from early August, with news that its investigational breast cancer drug OBI-822/821had  received Taiwan FDA approval to enter Phase III trials.
 
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue